Physician profile
Brian Mcmanus
NPI 1669585899
$254.82
in general payments reported to CMS, 2019-2025
10 companies · $24.19 in 2025
The $24.19 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $27.59 · 2023: $13.92 · 2025: $24.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $38.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $38.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $66.66 | 2019 | |
| Merck Sharp & Dohme LLC | $52.73 | 2019-2020 | |
| Edwards Lifesciences Corporation | $24.19 | 2025 | |
| Pfizer INC. | $20.12 | 2019 | |
| Amarin Pharma, INC. | $18.25 | 2019 | |
| Kerecis Limited | $16.07 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.32 | 2020 | |
| Pinnacle, INC | $13.92 | 2023 | |
| Novo Nordisk INC | $13.37 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Mcmanus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.